Search tips
Search criteria 


Logo of jexpmedHomeThis articleEditorsContactInstructions for Authors
J Exp Med. 2010 February 15; 207(2): 345–352.
PMCID: PMC2822613

A sex-specific role for androgens in angiogenesis


Mounting evidence suggests that in men, serum levels of testosterone are negatively correlated to cardiovascular and all-cause mortality. We studied the role of androgens in angiogenesis, a process critical in cardiovascular repair/regeneration, in males and females. Androgen exposure augmented key angiogenic events in vitro. Strikingly, this occurred in male but not female endothelial cells (ECs). Androgen receptor (AR) antagonism or gene knockdown abrogated these effects in male ECs. Overexpression of AR in female ECs conferred androgen sensitivity with respect to angiogenesis. In vivo, castration dramatically reduced neovascularization of Matrigel plugs. Androgen treatment fully reversed this effect in male mice but had no effect in female mice. Furthermore, orchidectomy impaired blood-flow recovery from hindlimb ischemia, a finding rescued by androgen treatment. Our findings suggest that endogenous androgens modulate angiogenesis in a sex-dependent manner, with implications for the role of androgen replacement in men.

The role of androgens in cardiovascular disease (CVD) remains controversial. Although men develop CVD earlier than women, consistent with increased atherosclerosis (Wingard et al., 1983; Shaw et al., 2006), repair/adaptation mechanisms may be enhanced in males (Joseph and Dyson, 1965). For example, male sex is associated with increased collateralization in patients with severe coronary artery lesions (Abaci et al., 1999). Androgens have been implicated in playing a detrimental role in CVD by numerous in vitro studies (McCrohon et al., 1999; Ng et al., 2003a,b), but in vivo and clinical studies fail to support this relationship (Liu et al., 2003; Wu and von Eckardstein, 2003; Harman, 2005). Indeed, some but not all cohort studies suggest that subnormal blood levels of testosterone are deleterious and correlate with increased cardiovascular risk factors and mortality (Araujo et al., 2007; Khaw et al., 2007; Laughlin et al., 2008; Tivesten et al., 2009).

Angiogenesis is a prerequisite for embryonic development and plays a critical role in adult physiological processes such as wound repair and in tissue responses to ischemia (Carmeliet, 2005). The cardiovascular system is an important target of androgen action (Liu et al., 2003), and although the effect of estrogen in angiogenesis has been studied extensively (Losordo and Isner, 2001), the role of androgens in this process remains largely unexplored.

Androgens have been implicated in the renewal of various tissues, including muscle and bone (Harman, 2005), but their potential role in the maintenance of cardiovascular repair mechanisms is unknown. As androgens have been implicated in the regulation of angiogenesis-related genes (Ng et al., 2003b; Death et al., 2004), we reasoned that androgens may play a role in angiogenesis, a process critical in the regenerative response after ischemia. To examine the role of androgens in angiogenesis, we used dihydrotestosterone (DHT), the most potent natural androgen that acts via the androgen receptor (AR). As testosterone action partly depends on its conversion to estradiol by the unique enzyme CYP19 (aromatase), whereas DHT cannot be aromatized, the use of DHT avoids the potentially confounding estrogen receptor (ER)–mediated effects of testosterone.


Androgens augment angiogenic events in vitro in male endothelial cells (ECs)

Male ECs treated with DHT demonstrated a dose-dependent increase in key angiogenic processes in vitro (Fig. 1). EC migration was assessed by two different methods. Cells were pretreated with varying doses of DHT (0, 4, 40, and 400 nM) and subsequently assessed using a Boyden chamber assay or a scratch wounding assay. Using the Boyden chamber assay, 24 h of DHT administration induced dose-dependent male EC migration (220 ± 22, 262 ± 38, and 336 ± 39% vs. 100% control value for DHT at 4, 40, and 400 nM, respectively; P < 0.001 using analysis of variance [ANOVA]; Fig. 1 B). Similar results were obtained using a scratch wounding assay. Migration by male ECs was augmented in a dose-dependent fashion (138 ± 7, 280 ± 23, and 306 ± 32%; P < 0.01 using ANOVA; Fig. 1 C). Interestingly, in both assays, addition of the AR antagonist hydroxyflutamide (HF) abrogated DHT-mediated EC migration (96 ± 6 and 94 ± 6% vs. 100% control value for 40 and 400 nM DHT + HF, respectively; P > 0.05; Fig. 1, B and C). DHT effects on tubulogenesis were assessed using both Matrigel and co-culture methods (Sieveking et al., 2008). Chronic exposure to DHT (72 h) induced a dose-dependent increase in male EC tubulogenesis (Fig. 1, D and E), as did 24 h of exposure (Fig. S1). Similarly, DHT augmented male EC proliferation in a dose-dependent fashion after 48 h (Fig. 1 F). Again, addition of HF abolished all androgen-mediated effects on these key angiogenic events, consistent with an AR-dependent mechanism (Fig. 1, B, C, E, and F).

Figure 1.
DHT augments key angiogenic events in vitro in male ECs via the AR. (A and B) Boyden chamber (cells were stained with Ulex lectin [UEA-1] and DAPI) and (C) scratch wounding assays of migration by male ECs pretreated with DHT or vehicle (0.1% EtOH) for ...

As an independent method to verify the pivotal involvement of AR in DHT-mediated angiogenic effects, we also assessed tubulogenesis in male ECs subjected to small interfering RNA (siRNA)–mediated knockdown of AR. DHT effects were also abolished in ECs exposed to AR siRNA (Fig. 1 G). DHT can also mediate effects via direct cross-reactivity at the ER at sufficiently high concentrations. Therefore, to further exclude any contribution to DHT effects via effects on ERs, we assessed tubulogenesis in male ECs treated with the highest concentration of DHT with or without the ER antagonist ICI182780. The addition of ICI182780 did not have any effect on DHT-mediated augmentation of tubulogenesis (Fig. 1 H). These findings are consistent with an AR-mediated angiogenic effect in male ECs.

Androgens do not augment angiogenic events in vitro in female ECs

Mounting evidence indicates that sex steroids regulate various vascular biological processes in a sex-dependent fashion (McCrohon et al., 1999; Ng et al., 2001; Ng et al., 2003b). For androgens, this is related to an approximately two- to fourfold increased AR expression in male vascular cells compared with females (McCrohon et al., 2000; Death et al., 2004). We therefore hypothesized that the proangiogenic effects of DHT observed in ECs may also be sex dependent. Unlike male ECs, exposure of female ECs to DHT had no effect on migration (Fig. 2, A and B), tubulogenesis (Fig. 2 C), or proliferation (P > 0.05; Fig. 2 D), consistent with androgen-mediated sex-specific effects. To further examine the role of the AR in mediating the sex-dependent effects of DHT on angiogenesis, we overexpressed the AR in female ECs (Fig. S2) and assessed tubulogenesis after exposure to DHT. Female ECs overexpressing the AR became responsive to DHT and displayed augmented tubulogenesis (114 ± 6% vs. 100% control value; P < 0.05 using the Student’s t test), albeit to a lesser extent than in male cells (Fig. 2 E). These findings indicate that the sex-specific effects of DHT on angiogenesis are at least in part mediated by sex differences in AR expression. As there are a variety of coregulators involved in AR signaling (Liu et al., 2003), it is also possible that many of these are also expressed in a sex-specific fashion and are important for androgenic modulation of angiogenesis.

Figure 2.
DHT does not augment key angiogenic events in vitro in female ECs. (A–D) Boyden chamber (A) and scratch wounding (B) assays of migration assessed after 6 and 24 h, respectively, Matrigel assays (C), and proliferation by female ECs treated with ...

The proangiogenic effect of androgens in vitro are vascular endothelial growth factor (VEGF) dependent

Next, to further elucidate the means by which DHT augmented migration, proliferation, and tubulogenesis in male ECs, cells exposed to DHT were assessed for the expression of various proangiogenic factors. Exposure of male ECs to DHT produced a dose-dependent increase in the production of VEGF, a key angiogenic growth factor (102.8 ± 7, 107.8 ± 7, 118.9 ± 6, and 147.2 ± 15 pg VEGF/100 µg of cell protein for 0, 4, 40, and 400 nM DHT, respectively; P = 0.0024; Fig. 3 A). Similarly, DHT induced dose-dependent increases in the messenger RNA (mRNA) expression of VEGF receptors 1 and 2 (Flt-1 and KDR, respectively; Fig. 3, B and C). However, flow cytometric assessment of surface VEGF receptor levels revealed that DHT augmented KDR but not Flt-1 expression in a dose-dependent manner (Fig. 3, D and E). As KDR is the chief mediator of the mitogenic/angiogenic action of VEGF in ECs, whereas Flt-1 may function as a negative regulator of VEGF action (Ferrara et al., 2003), our findings are consistent with a proangiogenic role for DHT through VEGF signaling via KDR. Furthermore, the addition of anti-VEGF antibody abrogated DHT-mediated increases in tubulogenesis (Fig. 3 F). Likewise, LY294002, an inhibitor of phosphoinositol 3-kinase (PI3K), a key enzyme in the PI3K–AKT pathway of VEGF signaling, inhibited DHT-mediated tubulogenesis (Fig. 3 F). These findings suggest that the proangiogenic effects of DHT in male ECs are VEGF dependent.

Figure 3.
Proangiogenic effects of DHT in male ECs is VEGF dependent. (A) Production of VEGF by male ECs exposed to DHT for 48 h. Total cell lysate protein was quantified and assayed via ELISA (n = 4 independent experiments). P = 0.002 using ANOVA for linear trend. ...

Endogenous androgens are necessary for angiogenesis in vivo in males but not females

Having demonstrated a sex-specific role for androgens in angiogenesis in vitro, we next assessed the role of androgens in angiogenesis in vivo, first using a Matrigel plug implantation model. Sexually mature male and female mice underwent gonadectomy or a sham gonadectomy followed by DHT administration. Orchidectomy markedly decreased in vivo vascularization of Matrigel plugs (27.3 ± 2% mm2 von Willebrand factor [vWF]+ cells/mm2 Matrigel vs. control as 100%; P < 0.0001 using ANOVA; Fig. 4 A). As can be observed in the representative image, these plugs were virtually acellular. Androgen treatment fully reversed the castration-related impairment of angiogenesis in males, returning vascularization of Matrigel plugs to levels not significantly different to controls (91 ± 6% mm2 vWF+ cells/mm2 Matrigel vs. control as 100%; P < 0.001).

Figure 4.
Endogenous androgens play a role in angiogenesis in males but not females. (A) Vascularization of Matrigel plugs harvested from male mice after 14 d, with representative images (n = 8/group; combined data from four independent experiments are shown). ...

Consistent with previous findings, ovariectomy attenuated Matrigel plug vascularization in females (Morales et al., 1995), albeit to levels more modest than in males (53 ± 8% mm2 vWF+ cells/mm2 Matrigel vs. control as 100%; P < 0.0001 using ANOVA; Fig. 4 B). In striking contrast to their male counterparts, gonadectomy-related impairment of angiogenesis in females was not reversed by DHT treatment (55 ± 6% vs. control as 100%; P < 0.0001 using ANOVA). In accordance with our in vitro findings, these data suggest that endogenous androgens play a role in angiogenesis in males but not females.

Endogenous androgens modulate ischemia-induced angiogenesis

Hypoxia is one of the most potent angiogenic stimuli (Ceradini and Gurtner, 2005). To investigate the role of androgens in ischemia-induced angiogenesis, we used a mouse model of hindlimb ischemia involving the unilateral ligation and removal of the femoral artery (Couffinhal et al., 1998). Male mice were randomized to orchidectomy with or without DHT treatment or a sham orchidectomy. Laser Doppler perfusion imaging demonstrated that orchidectomy markedly inhibited the rate of recovery from hindlimb ischemia (laser Doppler perfusion index [LDPI] ischemic/nonischemic ratio after 11 d: control, 0.54 ± 0.04; castrate, 0.39 ± 0.04; P < 0.05; Fig. 5 A). In functional assessments of the ischemic hindlimbs, orchidectomized animals also displayed impaired recovery in foot movement and ischemic damage (Fig. S3). Interestingly, DHT not only rescued the orchidectomy-induced impairment of blood flow recovery but also enhanced recovery from ischemia, with improvements in flow detectable as early as day 3 and significant by day 5 after ischemia (LDPI at day 5 after ischemia: control, 0.28 ± 0.04; orchidectomized + DHT, 0.4 ± 0.05; P < 0.05 vs. orchidectomized mice; Fig. 5 A). These findings were also borne out in the functional assessments of recovery (Fig. S3). The serial changes in perfusion observed after femoral artery ligation have previously been shown to correlate with changes in vessel density as determined by histological analysis (Couffinhal et al., 1998). As early as day 7, immunohistochemical staining of the adductor muscles of the ischemic hindlimbs revealed that capillary density was impaired in orchidectomized mice and augmented in DHT-treated orchidectomized mice (0.17 ± 0.01 and 0.27 ± 0.01 vs. 0.22 ± 0.01 capillaries/myofiber for orchidectomized mice, orchidectomized + DHT mice, and controls, respectively; P < 0.001 using ANOVA; Fig. 5, B and C), consistent with the findings observed for limb perfusion. Mean vessel diameter was also significantly smaller in orchidectomized mice (P < 0.001; Fig. 5 D). Interestingly, mean vessel diameter was also smaller in orchidectomized mice receiving DHT, but DHT treatment appeared to mitigate the effects of castration. These data suggest that, in the context of ischemia, endogenous androgens influence the rate and extent of ischemia-induced angiogenesis and play a role in arteriogenesis.

Figure 5.
Endogenous androgens modulate ischemia-induced angiogenesis. (A) LDPI. Limb perfusion ratio (ischemic/nonischemic) is presented with representative images (n = 8/group; combined data from four independent experiments are shown). Differences between groups ...

To elucidate the mechanisms of androgen-induced angiogenesis in the context of hindlimb ischemia, we assessed the early expression of angiogenesis- and ischemia-related genes. Notably, 3 d after ischemia, orchidectomy significantly reduced the expression of hypoxia-inducible factor 1α (HIF-1α; 0.5 ± 0.1 vs. 1.8 ± 0.2 relative mRNA expression ischemic/nonischemic for orchidectomized mice vs. controls, respectively; P < 0.05 using ANOVA) and stromal cell–derived factor 1α (SDF-1α; 0.7 ± 0.1 vs. 2.4 ± 0.1 relative mRNA expression ischemic/nonischemic for orchidectomized mice vs. controls, respectively; P < 0.05 using ANOVA), which are key factors in the coordination of angiogenic gene expression and progenitor cell migration and homing, respectively (Fig. 5, E and F, respectively; Ceradini et al., 2004). In stark contrast, DHT treatment of orchidectomized mice augmented expression of HIF-1α (3 ± 0.8; P < 0.01) and SDF-1α (3.6 ± 0.9; P < 0.01). These mice also demonstrated increased expression of KDR (3 ± 0.8 vs. 0.6 for orchidectomized + DHT vs. controls, respectively; P < 0.01 using ANOVA; Fig. 5 G), providing support for a role of DHT in VEGF signaling in vivo. Furthermore, similar trends were observed for VEGF and neuropillin-1 (Fig. S4). HIF-1α is the key subunit to HIF-1, which is a critical, genome-wide transcription regulator responsible for oxygen homeostasis and responsive to hypoxic stress (Semenza, 2002; Ceradini and Gurtner, 2005). It drives the expression of >100 genes, including key genes associated with angiogenesis such as VEGF and its receptors (Semenza, 2002). It is noteworthy that androgens have been associated with HIF-1 expression in the prostate (Boddy et al., 2005). Hence, it is possible that in addition to the direct effects of DHT, the increases observed for SDF-1α and KDR in DHT-treated mice are also related to induction of HIF-1α (Ceradini et al., 2004). There were trends toward a reduction in VEGF expression in orchidectomized animals and an increase with DHT treatment that were not statistically significant. Nevertheless, given the critical role of HIF-1α in inducing VEGF-related angiogenic events in ischemia and an increased expression of KDR, our in vivo findings are compatible with a role for VEGF in this context. Overall, these findings suggest that endogenous androgens play a role in the coordination of ischemia-mediated angiogenesis by the regulation of key angiogenesis-related genes, including HIF-1α and SDF-1α.

Androgens modulate ischemia-induced angiogenic/progenitor cell mobilization

It is now clear that the mobilization of various angiogenic/progenitor cells from the bone marrow to sites of ischemia is critical for neovascularization (Sieveking and Ng, 2009). Because the spleen serves as a reservoir for peripheral stem/progenitor cells (Heeschen et al., 2003), to further elucidate the mechanisms of androgen-induced angiogenesis in hindlimb ischemia, the early mobilization of angiogenic/progenitor cells was assessed in both the bone marrow and the spleen. Mononuclear cells (MNCs) staining positive for ulex lectin and uptake of Dil-acetylated low density lipoprotein (AcLDL) represent a heterogeneous population of cells with angiogenic activity (Asahara et al., 1997). Although the precise role of these cells in angiogenesis has been debated, these cells have been reported to augment angiogenesis in a paracrine fashion through the secretion of various growth factors (Heil et al., 2004; Sieveking et al., 2008). In females, estrogen has also been demonstrated to mobilize bone marrow–derived angiogenic/progenitor cells that participate in cardiovascular regeneration (Iwakura et al., 2006). Similarly, the findings of this study show that androgens modulate the mobilization of angiogenic cells. Orchidectomy markedly decreased the numbers of ulex+/AcLDL+ cells in the bone marrow (22.8 ± 1 vs. 13.4 ± 0.9 cells/200× field for control vs. orchidectomized mice, respectively; P < 0.001 using ANOVA; Fig. 6 A) and the spleen (20.6 ± 0.8 vs. 15.2 ± 0.7 cells/200× field for control vs. orchidectomized mice, respectively; P < 0.001 using ANOVA; Fig. 6 B). DHT treatment rescued castration-mediated decline in ulex+/AcLDL+ angiogenic cells in both the spleen (17.8 ± 0.9 cells/200× field; P > 0.05 using ANOVA) and the bone marrow (31.7 ± 5 cells/200× field; P < 0.001 using ANOVA). SDF-1α is a key chemokine in the migration and homing of bone marrow–derived progenitor cells to sites of ischemia, and is itself a ligand for the receptor CXCR4 (Jin et al., 2006); therefore, we also assessed the levels of CXCR4+/Sca-1+ progenitor cells after induction of hindlimb ischemia. Consistent with increased expression of SDF-1α, orchidectomized mice receiving DHT had significantly elevated numbers of CXCR4+/Sca-1+ cells present in the bone marrow at day 3 after ischemia (0.8 ± 0.2% vs. 0.4 ± 0.07% of MNCs for orchidectomized + DHT vs. controls, respectively; P < 0.05 using ANOVA; Fig. 6 C). Trends similar to those seen for ulex+/AcLDL+ cells were observed in the spleen for CXCR4+/Sca-1+ cells (i.e., decrease with castration and increase with DHT treatment), but these were not statistically significant (Fig. 6 D). The mobilization of cells from the bone marrow to the periphery is a highly coordinated, time-dependent event. Therefore, because sampling took place at day 3, it is possible that the significantly elevated numbers of Sca-1+/CXCR4+ cells in the bone marrow would not correspond to higher levels in the periphery until a later time point. Overall, our findings suggest that androgens play a role in the proliferation and mobilization of circulating angiogenic cell populations in the context of ischemia.

Figure 6.
Endogenous androgens modulate angiogenic/progenitor cell mobilization in response to ischemia. (A and B) Ulex+/AcLDL+ cells in the bone marrow (A) and spleen (B). Cells were seeded at a density of 5 × 106 cells/mm2 and after 4 d were assessed ...

Finally, in light of the well-established effects of androgens on erythropoiesis (Kennedy and Gilbertsen, 1957), we assessed erythroid progenitor cell levels, as these cells have been demonstrated to augment angiogenesis (Sasaki et al., 2007). Gonadal status had no effect on the numbers of granulocyte/macrophage progenitors present in the bone marrow or the spleen (Fig. 6, E and F). However, consistent with the enhanced recovery from ischemia observed in orchidectomized mice treated with DHT, erythroid progenitors were significantly elevated in these mice in both the bone marrow (29.5 ± 2 vs. 20.5 ± 1 erythroid CFUs/105 MNCs for orchidectomized + DHT vs. control, respectively; P < 0.01 using ANOVA; Fig. 6 G) and the spleen (10.6 ± 1 vs. 5.5 ± 1 erythroid CFUs/105 MNCs for orchidectomized + DHT vs. control, respectively; P < 0.01 using ANOVA; Fig. 6 H). These data suggest that the enhanced recovery from hindlimb ischemia seen in orchidectomized males receiving DHT may be mediated in part by increased mobilization of erythroid progenitors. In toto, the data presented in this report suggest that endogenous androgens are necessary in the coordination of neovascularization in response to critical ischemia and that consequent proangiogenic effects of DHT in this context are mediated in part through increased angiogenic/progenitor cell mobilization.

In summary, we report a sex-specific role for androgens in angiogenesis. Androgens stimulate key angiogenic events in male but not female cells in vitro, and these sex-specific proangiogenic effects are mediated via the AR. In addition, we report that endogenous androgens modulate angiogenesis in males but not females in vivo. Moreover, in males, endogenous androgens are involved in the coordination and enhancement of neovascularization in the context of ischemic injury. Our findings suggest that androgens regulate vascular regeneration in a sex-dependent manner. Given the age-related decline of androgens, our findings have implications for the role of androgen replacement in men. Additionally, these data may explain in part some of the observed sex differences in the outcomes of CVD.


Cell culture.

Human umbilical vein ECs (HUVECs), freshly isolated as described previously (Sieveking et al., 2008), were used in this study as they are well validated in the study of angiogenesis and enabled the assessment of a variety of male and female donors by primary cell harvest and culture. The sex of HUVECs derived from male and female newborns was confirmed via PCR analysis of the X-Y amelogenin gene (Akane, 1998). Cells (passages 2–4) were grown in phenol red–free endothelial growth medium supplemented with FBS that was stripped of endogenous steroids by 2% charcoal-dextran treatment. Cells were treated with the nonaromatizable androgen DHT (0, 4, 40, or 400 nM) with and without the AR antagonist HF (40 µM), and assayed for migration, proliferation, and vascular network formation as previously described (Sieveking et al., 2008), and a traditional Matrigel assay. Umbilical cords were obtained under ethical approvals of the Sydney South West Area Health Service Human Ethics Committee.

AR silencing/overexpression.

AR silencing was assessed using a commercially available plasmid containing an oligonucleotide encoding an AR siRNA (pKD-AR-v2; Millipore). To increase AR expression in female cells, we used an AR expression plasmid (pSVARo; provided by A.O. Brinkmann, Erasmus University Rotterdam, Rotterdam, Netherlands).

DHT and VEGF signaling in male ECs.

After exposure to DHT for 48 h, cell lysates were assayed via ELISA (R&D Systems). Additionally, the effect of DHT on male EC tubulogenesis was assessed in the presence of 1 µg/ml anti-VEGF antibody (R&D Systems) or 10 µM LY294002 (Merck), an inhibitor of PI3K. Expression of Flt-1 and KDR was assessed via flow cytometry using PE-conjugated antibodies against each antigen (R&D Systems).

Real-time RT-PCR.

Real-time RT-PCR was performed in triplicate using iQ SYBR Green Supermix and the iCycler Real-Time PCR Detection System (Bio-Rad Laboratories). For the animal studies, the relative expression (R) of each target mRNA was calculated based on the Pfaffl equation (Pfaffl, 2001), as follows: R = (Etarget)ΔCttarget/(Ereference)ΔCtreference, where ΔCt = Ctischemic − Ctnonischemic. The reference was β-actin or β2-microglobuin mRNA.

Animal studies.

All animal studies were performed under ethical approvals of the Sydney South West Area Health Service Animal Welfare Committee. Male and female C57Bl6/J mice at 6 wk of age were randomized to orchidectomy, ovariectomy, or sham castration. 10 d later, castrated mice received a 1-cm subdermal silastic implant filled with crystalline DHT.

Matrigel plug implantation model.

Matrigel plug assays were performed as described previously (Passaniti et al., 1992). Commercially available Matrigel (BD) without phenol red was supplemented with 100 ng/ml of basic fibroblast growth factor.

Hindlimb ischemia model.

Hindlimb ischemia and subsequent perfusion (Moor Instruments) and monitoring was performed as described previously (Stabile et al., 2003).

Angiogenic/progenitor cell mobilization.

For flow cytometric analysis (FC500; Beckman Coulter), MNCs were stained with PE-conjugated antibodies against SCA-1 (BioLegend) and FITC-conjugated antibodies against CXCR4 (BD) with matched isotype controls. CFU assays for granulocyte/macrophage and erythroid progenitors were set up in methylcellulose medium (MethoCult; STEMCELL Technologies Inc.).

Statistical analysis.

Data are expressed as means ± SEM. Comparisons between groups were performed using a two-tailed t test or by a one-way ANOVA with post hoc analyses for pairwise comparisons (Newman-Keuls multiple comparison). Prism software (version 4.00; GraphPad Software, Inc.) for Windows was used for statistical analysis.

Online supplemental material.

Fig. S1 depicts a dose-dependent augmentation of Matrigel-based tubulogenesis in male ECs exposed to DHT for 24 h. In Fig. S2, we show differential gene expression of the AR in male and female ECs as well as female ECs transfected with an AR expression vector. Fig. S3 demonstrates the effect of castration and DHT treatment on the functional recovery of male mice subjected to femoral artery ligation. Fig. S4 shows the expression of angiogenesis-related genes in response to hindlimb ischemia. Online supplemental material is available at


We wish to thank Professor R.H. Karas for providing scientific advice during the preparation of this paper.

This study was supported by a grant from the National Health and Medical Research Council (457534). D.P. Sieveking was supported by a postgraduate support grant from GlaxoSmithKline Australia.

The authors have no conflicting financial interests.


Abbreviations used:

Dil-acetylated low density lipoprotein
analysis of variance
androgen receptor
cardiovascular disease
endothelial cell
estrogen receptor
hypoxia-inducible factor 1
laser Doppler perfusion index
mononuclear cell
messenger RNA
phosphoinositol 3-kinase
stromal cell–derived factor 1α
small interfering RNA
vascular endothelial growth factor
von Willebrand factor


  • Abaci A., Ogǧuzhan A., Kahraman S., Eryol N.K., Unal S., Arinç H., Ergin A. 1999. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation. 99:2239–2242 [PubMed]
  • Akane A. 1998. Sex determination by PCR analysis of the X-Y amelogenin gene. Methods Mol. Biol. 98:245–249 [PubMed]
  • Araujo A.B., Kupelian V., Page S.T., Handelsman D.J., Bremner W.J., McKinlay J.B. 2007. Sex steroids and all-cause and cause-specific mortality in men. Arch. Intern. Med. 167:1252–1260 10.1001/archinte.167.12.1252 [PubMed] [Cross Ref]
  • Asahara T., Murohara T., Sullivan A., Silver M., van der Zee R., Li T., Witzenbichler B., Schatteman G., Isner J.M. 1997. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 275:964–967 10.1126/science.275.5302.964 [PubMed] [Cross Ref]
  • Boddy J.L., Fox S.B., Han C., Campo L., Turley H., Kanga S., Malone P.R., Harris A.L. 2005. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin. Cancer Res. 11:7658–7663 10.1158/1078-0432.CCR-05-0460 [PubMed] [Cross Ref]
  • Carmeliet P. 2005. Angiogenesis in life, disease and medicine. Nature. 438:932–936 10.1038/nature04478 [PubMed] [Cross Ref]
  • Ceradini D.J., Gurtner G.C. 2005. Homing to hypoxia: HIF-1 as a mediator of progenitor cell recruitment to injured tissue. Trends Cardiovasc. Med. 15:57–63 10.1016/j.tcm.2005.02.002 [PubMed] [Cross Ref]
  • Ceradini D.J., Kulkarni A.R., Callaghan M.J., Tepper O.M., Bastidas N., Kleinman M.E., Capla J.M., Galiano R.D., Levine J.P., Gurtner G.C. 2004. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10:858–864 10.1038/nm1075 [PubMed] [Cross Ref]
  • Couffinhal T., Silver M., Zheng L.P., Kearney M., Witzenbichler B., Isner J.M. 1998. Mouse model of angiogenesis. Am. J. Pathol. 152:1667–1679 [PubMed]
  • Death A.K., McGrath K.C., Sader M.A., Nakhla S., Jessup W., Handelsman D.J., Celermajer D.S. 2004. Dihydrotestosterone promotes vascular cell adhesion molecule-1 expression in male human endothelial cells via a nuclear factor-kappaB-dependent pathway. Endocrinology. 145:1889–1897 10.1210/en.2003-0789 [PubMed] [Cross Ref]
  • Ferrara N., Gerber H.P., LeCouter J. 2003. The biology of VEGF and its receptors. Nat. Med. 9:669–676 10.1038/nm0603-669 [PubMed] [Cross Ref]
  • Harman S.M. 2005. Testosterone in older men after the Institute of Medicine Report: where do we go from here? Climacteric. 8:124–135 10.1080/13697130500042417 [PubMed] [Cross Ref]
  • Heeschen C., Aicher A., Lehmann R., Fichtlscherer S., Vasa M., Urbich C., Mildner-Rihm C., Martin H., Zeiher A.M., Dimmeler S. 2003. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 102:1340–1346 10.1182/blood-2003-01-0223 [PubMed] [Cross Ref]
  • Heil M., Ziegelhoeffer T., Mees B., Schaper W. 2004. A different outlook on the role of bone marrow stem cells in vascular growth: bone marrow delivers software not hardware. Circ. Res. 94:573–574 10.1161/01.RES.0000124603.46777.EB [PubMed] [Cross Ref]
  • Iwakura A., Shastry S., Luedemann C., Hamada H., Kawamoto A., Kishore R., Zhu Y., Qin G., Silver M., Thorne T., et al. 2006. Estradiol enhances recovery after myocardial infarction by augmenting incorporation of bone marrow-derived endothelial progenitor cells into sites of ischemia-induced neovascularization via endothelial nitric oxide synthase-mediated activation of matrix metalloproteinase-9. Circulation. 113:1605–1614 10.1161/CIRCULATIONAHA.105.553925 [PubMed] [Cross Ref]
  • Jin D.K., Shido K., Kopp H.G., Petit I., Shmelkov S.V., Young L.M., Hooper A.T., Amano H., Avecilla S.T., Heissig B., et al. 2006. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat. Med. 12:557–567 10.1038/nm1400 [PMC free article] [PubMed] [Cross Ref]
  • Joseph J., Dyson M. 1965. Sex differences in the rate of tissue regeneration in the rabbit’s ear. Nature. 208:599–600 10.1038/208599a0 [Cross Ref]
  • Kennedy B.J., Gilbertsen A.S. 1957. Increased erythropoiesis induced by androgenic-hormone therapy. N. Engl. J. Med. 256:719–726 [PubMed]
  • Khaw K.T., Dowsett M., Folkerd E., Bingham S., Wareham N., Luben R., Welch A., Day N. 2007. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 116:2694–2701 10.1161/CIRCULATIONAHA.107.719005 [PubMed] [Cross Ref]
  • Laughlin G.A., Barrett-Connor E., Bergstrom J. 2008. Low serum testosterone and mortality in older men. J. Clin. Endocrinol. Metab. 93:68–75 10.1210/jc.2007-1792 [PubMed] [Cross Ref]
  • Liu P.Y., Death A.K., Handelsman D.J. 2003. Androgens and cardiovascular disease. Endocr. Rev. 24:313–340 10.1210/er.2003-0005 [PubMed] [Cross Ref]
  • Losordo D.W., Isner J.M. 2001. Estrogen and angiogenesis: A review. Arterioscler. Thromb. Vasc. Biol. 21:6–12 [PubMed]
  • McCrohon J.A., Jessup W., Handelsman D.J., Celermajer D.S. 1999. Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1. Circulation. 99:2317–2322 [PubMed]
  • McCrohon J.A., Death A.K., Nakhla S., Jessup W., Handelsman D.J., Stanley K.K., Celermajer D.S. 2000. Androgen receptor expression is greater in macrophages from male than from female donors. A sex difference with implications for atherogenesis. Circulation. 101:224–226 [PubMed]
  • Morales D.E., McGowan K.A., Grant D.S., Maheshwari S., Bhartiya D., Cid M.C., Kleinman H.K., Schnaper H.W. 1995. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation. 91:755–763 [PubMed]
  • Ng M.K., Jessup W., Celermajer D.S. 2001. Sex-related differences in the regulation of macrophage cholesterol metabolism. Curr. Opin. Lipidol. 12:505–510 10.1097/00041433-200110000-00005 [PubMed] [Cross Ref]
  • Ng M.K., Nakhla S., Baoutina A., Jessup W., Handelsman D.J., Celermajer D.S. 2003a. Dehydroepiandrosterone, an adrenal androgen, increases human foam cell formation: a potentially pro-atherogenic effect. J. Am. Coll. Cardiol. 42:1967–1974 10.1016/j.jacc.2003.07.024 [PubMed] [Cross Ref]
  • Ng M.K., Quinn C.M., McCrohon J.A., Nakhla S., Jessup W., Handelsman D.J., Celermajer D.S., Death A.K. 2003b. Androgens up-regulate atherosclerosis-related genes in macrophages from males but not females: molecular insights into gender differences in atherosclerosis. J. Am. Coll. Cardiol. 42:1306–1313 10.1016/j.jacc.2003.07.002 [PubMed] [Cross Ref]
  • Passaniti A., Taylor R.M., Pili R., Guo Y., Long P.V., Haney J.A., Pauly R.R., Grant D.S., Martin G.R. 1992. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest. 67:519–528 [PubMed]
  • Pfaffl M.W. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e45 10.1093/nar/29.9.e45 [PMC free article] [PubMed] [Cross Ref]
  • Sasaki S., Inoguchi T., Muta K., Abe Y., Zhang M., Hiasa K., Egashira K., Sonoda N., Kobayashi K., Takayanagi R., Nawata H. 2007. Therapeutic angiogenesis by ex vivo expanded erythroid progenitor cells. Am. J. Physiol. Heart Circ. Physiol. 292:H657–H665 10.1152/ajpheart.00343.2006 [PubMed] [Cross Ref]
  • Semenza G.L. 2002. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 8(Suppl.):S62–S67 10.1016/S1471-4914(02)02317-1 [PubMed] [Cross Ref]
  • Shaw L.J., Bairey Merz C.N., Pepine C.J., Reis S.E., Bittner V., Kelsey S.F., Olson M., Johnson B.D., Mankad S., Sharaf B.L., et al. ; WISE Investigators 2006. Insights from the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation (WISE) study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J. Am. Coll. Cardiol. 47(Suppl. 1):S4–S20 10.1016/j.jacc.2005.01.072 [PubMed] [Cross Ref]
  • Sieveking D.P., Ng M.K. 2009. Cell therapies for therapeuticangiogenesis: back to the bench. Vasc. Med. 14:153–166 10.1177/1358863X08098698 [PubMed] [Cross Ref]
  • Sieveking D.P., Buckle A., Celermajer D.S., Ng M.K. 2008. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. J. Am. Coll. Cardiol. 51:660–668 10.1016/j.jacc.2007.09.059 [PubMed] [Cross Ref]
  • Stabile E., Burnett M.S., Watkins C., Kinnaird T., Bachis A., la Sala A., Miller J.M., Shou M., Epstein S.E., Fuchs S. 2003. Impaired arteriogenic response to acute hindlimb ischemia in CD4-knockout mice. Circulation. 108:205–210 10.1161/01.CIR.0000079225.50817.71 [PubMed] [Cross Ref]
  • Tivesten A., Vandenput L., Labrie F., Karlsson M.K., Ljunggren O., Mellström D., Ohlsson C. 2009. Low serum testosterone and estradiol predict mortality in elderly men. J. Clin. Endocrinol. Metab. 94:2482–2488 [PubMed]
  • Wingard D.L., Suarez L., Barrett-Connor E. 1983. The sex differential in mortality from all causes and ischemic heart disease. Am. J. Epidemiol. 117:165–172 [PubMed]
  • Wu F.C., von Eckardstein A. 2003. Androgens and coronary artery disease. Endocr. Rev. 24:183–217 10.1210/er.2001-0025 [PubMed] [Cross Ref]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press